Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
CJC-1295, also referred to as Mod GRF 1-29, has been investigated as an analog of somatocrinin, with potential to stimulate growth hormone-releasing hormone (GHRH) receptors
Tirzepatide, better known as Zepbound for weight loss and Mounjaro for treatment of type 2 diabetes, helped patients lose more than 20% of their starting body weight across the reviewed studies
PlexusDx sources all medications from licensed 503A compounding pharmacies, which follow strict FDA regulations for quality, sterility, and potency
Clinical research has shown that many individuals using these medications experience significant and sustained weight loss
Tirzepatide offers cardiovascular protection (38% reduction in heart failure events), liver fat reduction and MASH resolution (44-62% of patients), sleep apnea improvement (up to 63% AHI reduction), blood pressure reduction (up to 5.8 mmHg), cholesterol improvement (24.9% triglyceride reduction), kidney protection (33% fewer major kidney events), joint pain reduction, PCOS symptom improvement, and systemic inflammation reduction
About the Study In the present study, researchers examined the associations between genetically predicted GLP-1R activation and mental health outcomes
US$ 20.85
US$ 22.52
US$ 25.99
US$ 28.94
US$ 26.43
US$ 26.82
US$ 22.81
US$ 21.72
US$ 29.68
